Evidence map›Paper›PMID 38261033›Full record

ArticleJournal of neural transmission (Vienna, Austria : 1996)2024

Functional AGXT2 SNP rs180749 variant and depressive symptoms: Baseline data from the Aidai Cohort Study in Japan.

Hiroshi Kumon, Yoshihiro Miyake, Yuta Yoshino, Jun-Ichi Iga, Keiko Tanaka, Hidenori Senba, Eizen Kimura, Takashi Higaki, Bunzo Matsuura, Ryuichi Kawamoto and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of neural transmission (Vienna, Austria : 1996), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Hiroshi Kumon *Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Ehime, 791-0295, Japan.
Yoshihiro Miyake *Department of Epidemiology and Public Health, Ehime University Graduate School of Medicine, Ehime, Japan.
Yuta YoshinoDepartment of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Ehime, 791-0295, Japan.
Jun-Ichi IgaDepartment of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Ehime, 791-0295, Japan. igajunichi@hotmail.com.ORCID 0000-0003-4409-3096
Keiko TanakaDepartment of Epidemiology and Public Health, Ehime University Graduate School of Medicine, Ehime, Japan.
Hidenori SenbaDepartment of Epidemiology and Public Health, Ehime University Graduate School of Medicine, Ehime, Japan.
Eizen KimuraIntegrated Medical and Agricultural School of Public Health, Ehime University, Ehime, Japan.
Takashi HigakiDepartment of Regional Pediatrics and Perinatology, Ehime University Graduate School of Medicine, Ehime, Japan.
Bunzo MatsuuraDepartment of Lifestyle-Related Medicine and Endocrinology, Ehime University Graduate School of Medicine, Ehime, Japan.
Ryuichi KawamotoIntegrated Medical and Agricultural School of Public Health, Ehime University, Ehime, Japan.
Shu-Ichi UenoDepartment of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Ehime, 791-0295, Japan.
Ehime University · JPEhime University Hospital · JPMatsuyama Shimin Hospital · JP

Funding

Japan Society for the Promotion of Science London 18H02752Japan Society for the Promotion of Science London 20K10249Japan Society for the Promotion of Science London 21H03199Japan Society for the Promotion of Science London 22K07562Japan Society for the Promotion of Science London 22K07597Japan Society for the Promotion of Science London 23K07016
6 · The paper itself

Abstract

No study has shown the relationship between alanine-glyoxylate aminotransferase 2 (AGXT2) single nucleotide polymorphisms (SNPs) and depressive symptoms. The present case-control study examined this relationship in Japanese adults. Cases and control participants were selected from those who participated in the baseline survey of the Aidai Cohort Study, which is an ongoing cohort study. Cases comprised 280 participants with depressive symptoms based on a Center for Epidemiologic Studies Depression Scale (CES-D) score ≥ 16. Control participants comprised 2034 participants without depressive symptoms based on the CES-D who had not been diagnosed by a physician as having depression or who had not been currently taking medication for depression. Adjustment was made for age, sex, smoking status, alcohol consumption, leisure time physical activity, education, body mass index, hypertension, dyslipidemia, and diabetes mellitus. Compared with the GG genotype of rs180749, both the GA and AA genotypes were significantly positively associated with the risk of depressive symptoms assessed by the CES-D: the adjusted odds ratios for the GA and AA genotypes were 2.83 (95% confidence interval [CI] 1.23-8.24) and 3.10 (95% CI 1.37-8.92), respectively. The TGC haplotype of rs37370, rs180749, and rs16899974 was significantly inversely related to depressive symptoms (crude OR 0.67; 95% CI 0.49-0.90), whereas the TAC haplotype was significantly positively associated with depressive symptoms (crude OR 1.24; 95% CI 1.01-1.52). This is the first study to show significant associations between AGXT2 SNP rs180749, the TGC haplotype, and the TAC haplotype and depressive symptoms.

Indexed as

DepressionPolymorphism, Single NucleotideAdultCase-Control StudiesCohort StudiesGenotypeHumansJapanTransaminasesAlanine-glyoxylate transaminaseTransaminasesAGXT2CES-DDepressive symptomsFunctional single nucleotide polymorphismsJapanese

Identifiers

PMID38261033
PMCPMC10874328
OpenAlexW4391137840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.